Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Serotonin Transporter and Serotonin Receptors

  • Chapter
  • First Online:
Pharmacotherapy of Pulmonary Hypertension

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 218))

Abstract

The nature of the primary defect responsible for triggering and maintaining pulmonary artery smooth muscle (PA-SMC) proliferation in pulmonary artery hypertension (PAH) is poorly understood but may be either an inherent characteristic of PA-SMCs or a secondary response to an external abnormality, such as upregulation of growth factors. The serotonin hypothesis of PAH originated in the 1960s after an outbreak of the disease was reported among patients taking the anorexigenic drugs aminorex. The anorexiant dexfenfluramine which inhibits 5-HT neuronal uptake, causes 5-HT platelet depletion, and increases plasma levels of 5-HT, was then shown to increase the relative risk of developing PAH in the adults. More recently, the incidence of persistent pulmonary hypertension of the newborn was shown to be increased by the use of selective 5-HT reuptake inhibitors taken in late pregnancy. Serotonin is a vasoconstrictor and a potent mitogen for pulmonary smooth muscle cells (PA-SMC), an effect which depends upon activity of both the 5-HT transporter (5-HTT) and the 5-HT receptors. Expression analysis of lung tissues from PAH patients undergoing lung transplantation revealed an increased expression of the 5-HT transporter (5-HTT) and an enhanced proliferative growth response of isolated pulmonary arterial smooth muscle cells (PASMC) to 5-HT. Serotonin is contained in platelets but is also synthesized by pulmonary endothelial cells which express tryptophan hydroxylase 1, the rate-limiting enzyme of 5-HT synthesis. While inhibitors of 5-HTT and of 5-HT2B receptors can reverse experimental PH, 5-HTT-overexpressing mice spontaneously develop PH. In patients with chronic lung disease, a close association has been found between a 5-HTT gene polymorphism and the severity of pulmonary hypertension. Agents capable of selectively inhibiting 5-HTT-mediated PA-SMC proliferation deserve to be investigated as potential treatments for pulmonary hypertension. However, the 5-HT pathway is still studied only on a preclinical level and the usefulness of drugs interacting with the 5-HT pathway remains to be established in human PAH.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335:609–616

    Article  PubMed  CAS  Google Scholar 

  • Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579–587

    Article  PubMed  CAS  Google Scholar 

  • Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, DePinho RA (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97:527–538

    Article  PubMed  CAS  Google Scholar 

  • Ciccarelli E, Camanni F (1996) Diagnosis and drug therapy of prolactinoma. Drugs 51:954–965

    Article  PubMed  CAS  Google Scholar 

  • Darmon MC, Guibert B, Leviel V, Ehret M, Maitre M, Mallet J (1988) Sequence of two mRNAs encoding active rat tryptophan hydroxylase. J Neurochem 51:312–316

    Article  PubMed  CAS  Google Scholar 

  • Delaney C, Cornfield DN (2012) Risk factors for persistent pulmonary hypertension of the newborn. Pulm Circ 2:15–20

    Article  PubMed  CAS  Google Scholar 

  • Delaney C, Gien J, Grover TR, Roe G, Abman SH (2012) Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus. Am J Physiol Lung Cell Mol Physiol 301:L937–L944

    Article  Google Scholar 

  • Dennery PA, Spitz DR, Yang G, Tatarov A, Lee CS, Shegog ML (1998) Oxygen toxicity and iron accumulation in the lungs of mice lacking heme oxygenase-2. J Clin Invest 101:1001–1011

    Article  PubMed  CAS  Google Scholar 

  • Dewachter L, Adnot S, Fadel E, Humbert M, Maitre B, Barlier-Mur AM, Simonneau G, Hamon M, Naeije R, Eddahibi S (2006) Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am J Respir Crit Care Med 174:1025–1033

    Article  PubMed  CAS  Google Scholar 

  • Dumitrascu R, Kulcke C, Konigshoff M, Kouri F, Yang X, Morrell N, Ghofrani HA, Weissmann N, Reiter R, Seeger W, Grimminger F, Eickelberg O, Schermuly RT, Pullamsetti SS (2011) Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 37:1104–1118

    Article  PubMed  CAS  Google Scholar 

  • Eddahibi S, Adnot S (2002) Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res 3:9–13

    Article  PubMed  Google Scholar 

  • Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S (2000) Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105:1555–1562

    Article  PubMed  CAS  Google Scholar 

  • Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108:1141–1150

    PubMed  CAS  Google Scholar 

  • Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, Humbert M, Simonneau G, Hanoun N, Saurini F, Hamon M, Adnot S (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113:1857–1864

    Article  PubMed  CAS  Google Scholar 

  • Fanburg B, Lee S-L (1997) A new role for an old molecule: serotonin as a mitogen. Am J Physiol 272:L795–L806

    PubMed  CAS  Google Scholar 

  • Frishman WH, Huberfeld S, Okin S, Wang YH, Kumar A, Shareef B (1995) Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 35:541–572

    Article  PubMed  CAS  Google Scholar 

  • Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S (2005) Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111:2812–2819

    Article  PubMed  CAS  Google Scholar 

  • Guilluy C, Rolli-Derkinderen M, Tharaux PL, Melino G, Pacaud P, Loirand G (2007) Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem 282:2918–2928

    Article  PubMed  CAS  Google Scholar 

  • Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L, Savale L, Humbert M, Fadel E, Adnot S, Loirand G, Pacaud P (2009) RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med 179:1151–1158

    Article  PubMed  CAS  Google Scholar 

  • Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99:249–254

    Article  PubMed  CAS  Google Scholar 

  • Izikki M, Hanoun N, Marcos E, Savale L, Barlier-Mur AM, Saurini F, Eddahibi S, Hamon M, Adnot S (2007) Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 293:L1045–L1052

    Article  PubMed  CAS  Google Scholar 

  • Keegan A, Morecroft I, Smillie D, Hicks M, MacLean M (2001) Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension. Circ Res 89:1231–1239

    Article  PubMed  CAS  Google Scholar 

  • Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B (2012) Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 344:d8012

    Article  PubMed  Google Scholar 

  • Launay JM, Herve P, Peoc’h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129–1135

    Article  PubMed  CAS  Google Scholar 

  • Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR, Harmar AJ, Schmidt AM, Lukanidin E, Rabinovitch M (2005) Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 97:227–235

    Article  PubMed  CAS  Google Scholar 

  • Lee SL, Wang WW, Moore BJ, Fanburg BL (1991) Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ Res 68:1362–1368

    Article  PubMed  CAS  Google Scholar 

  • Lee SL, Wang WW, Fanburg BL (1998) Superoxide as an intermediate signal for serotonin-induced mitogenesis. Free Radic Biol Med 24:855–858

    Article  PubMed  Google Scholar 

  • Lee SL, Simon AR, Wang WW, Fanburg BL (2001) H(2)O(2) signals 5-HT-induced ERK MAP kinase activation and mitogenesis of smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 281:L646–L652

    PubMed  CAS  Google Scholar 

  • Lesch KP, Wolozin BL, Estler HC, Murphy DL, Rieder P (1993) Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm Gen Sect 91:67–72

    Article  PubMed  CAS  Google Scholar 

  • Liu Y, Suzuki YJ, Day RM, Fanburg BL (2004) Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 95:579–586

    Article  PubMed  CAS  Google Scholar 

  • Machado RD, Koehler R, Glissmeyer E, Veal C, Suntharalingam J, Kim M, Carlquist J, Town M, Elliott CG, Hoeper M, Fijalkowska A, Kurzyna M, Thomson JR, Gibbs SR, Wilkins MR, Seeger W, Morrell NW, Gruenig E, Trembath RC, Janssen B (2006) Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 173:793–797

    Article  PubMed  CAS  Google Scholar 

  • MacLean MR, Clayton RA, Templeton AG, Morecroft I (1996a) Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 119:277–282

    Article  PubMed  CAS  Google Scholar 

  • MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I (1996b) 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 119:917–930

    Article  PubMed  CAS  Google Scholar 

  • MacLean M, Herve P, Eddahibi S, Adnot S (2000) 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131:161–168

    Article  PubMed  CAS  Google Scholar 

  • MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen S, Sheward J, Colston J, Loughlin L, Nilsen M, Dempsie Y, Harmar A (2004) Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 109:2150–2155

    Article  PubMed  CAS  Google Scholar 

  • Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G, Hamon M, Adnot S, Eddahibi S (2004) Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94:1263–1270

    Article  PubMed  CAS  Google Scholar 

  • Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791–804

    Article  PubMed  CAS  Google Scholar 

  • Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR (1999) 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol 128:730–734

    Article  PubMed  CAS  Google Scholar 

  • Morecroft I, Loughlin L, Nilsen M, Colston J, Dempsie Y, Sheward J, Harmar A, MacLean MR (2005) Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther 313:539–548

    Article  PubMed  CAS  Google Scholar 

  • Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L, Nilsen M, MacLean MR (2007) Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49:232–236

    Article  PubMed  CAS  Google Scholar 

  • Ni W, Geddes TJ, Priestley JR, Szasz T, Kuhn DM, Watts SW (2008) The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br J Pharmacol 154:663–674

    Article  PubMed  CAS  Google Scholar 

  • Rondelet B, Van Beneden R, Kerbaul F, Motte S, Fesler P, McEntee K, Brimioulle S, Ketelslegers JM, Naeije R (2003) Expression of the serotonin 1b receptor in experimental pulmonary hypertension. Eur Respir J 22:408–412

    Article  PubMed  CAS  Google Scholar 

  • Rothman RB, Ayestas MA, Dersch CM, Baumann MH (1999) Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 100:869–875

    Article  PubMed  CAS  Google Scholar 

  • Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M (2003a) Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299:76

    Article  PubMed  CAS  Google Scholar 

  • Walther DJ, Peter JU, Winter S, Holtje M, Paulmann N, Grohmann M, Vowinckel J, Alamo-Bethencourt V, Wilhelm CS, Ahnert-Hilger G, Bader M (2003b) Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115:851–862

    Article  PubMed  CAS  Google Scholar 

  • White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR (2011) The serotonin transporter, gender, and 17beta oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 90:373–382

    Article  PubMed  CAS  Google Scholar 

  • Willers ED, Newman JH, Loyd JE, Robbins IM, Wheeler LA, Prince MA, Stanton KC, Cogan JA, Runo JR, Byrne D, Humbert M, Simonneau G, Sztrymf B, Morse JA, Knowles JA, Roberts KE, McElroy JJ, Barst RJ, Phillips JA 3rd (2006) Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 173:798–802

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM U955 and Département de Physiologie, Hôpital Henri Mondor, AP-HP, 94010, Créteil, France

    Serge Adnot, Amal Houssaini, Shariq Abid, Elisabeth Marcos & Valérie Amsellem

Authors
  1. Serge Adnot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amal Houssaini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shariq Abid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth Marcos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valérie Amsellem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Serge Adnot .

Editor information

Editors and Affiliations

  1. Faculte´ de Me´decine, Univ Paris-Sud, Le Kremlin Bicêtre, France

    Marc Humbert

  2. Dep of Anasthesia and Critical Care, Harvard Medical School Massachusetts General Hospital, Boston, Massachusetts, USA

    Oleg V. Evgenov

  3. Cardiovascular Research, Bayer Pharma AG, Wuppertal, Germany

    Johannes-Peter Stasch

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Adnot, S., Houssaini, A., Abid, S., Marcos, E., Amsellem, V. (2013). Serotonin Transporter and Serotonin Receptors. In: Humbert, M., Evgenov, O., Stasch, JP. (eds) Pharmacotherapy of Pulmonary Hypertension. Handbook of Experimental Pharmacology, vol 218. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38664-0_15

Download citation

Publish with us

Policies and ethics

Search

Navigation